The detection of circulating tumour cells by immunohistochemistry
Research type
Research Study
Full title
The detection of circulating tumour cells by immunohistochemistry on formalin fixed paraffin embedded cell blocks.
IRAS ID
209687
Contact name
Frederick Mayall
Contact email
Sponsor organisation
ANGLE Europe Ltd
Duration of Study in the UK
1 years, 2 months, 1 days
Research summary
This study examines the performance of a simplified method for capturing and typing circulating tumour cells (CTCs) for patients that have, or are likely to have, advanced metastatic carcinoma. This method combines two established commercially available technologies; Parsortix (Angle PLC) and CytoFoam Disc (Exmoor Innovations Ltd). The study will be divided in to two parts. There will be an initial study of 10 cases. If CTCs can recovered from the blood of the first 10 cases, then a further 40 cases will be tested.
A 10 ml blood sample is required.
Angle’s Parsortix technology captures circulating tumour cells (CTCs) from blood. The resulting “liquid biopsy” enables the genetic and protein analysis of the patient’s cancer which has the potential to help direct optimal therapy.
Cytofoam Disc is a hydrogel sponge that absorbs cells, from a liquid, within its pores so that they can be examined in formalin fixed paraffin embedded sections, of the type that are used for all routine diagnostic histopathology.
The study will be divided in to two parts. There will be an initial study of 10 cases. If CTCs can recovered from the blood of any of the first 10 cases, then a further 40 cases will be tested. If no CTCs can be recovered from the blood of the first 10 cases then the study will end. See the uploaded protocol.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
16/WM/0418
Date of REC Opinion
14 Oct 2016
REC opinion
Further Information Favourable Opinion